These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27100398)

  • 1. Cardiovascular Disease After Aromatase Inhibitor Use.
    Haque R; Shi J; Schottinger JE; Chung J; Avila C; Amundsen B; Xu X; Barac A; Chlebowski RT
    JAMA Oncol; 2016 Dec; 2(12):1590-1597. PubMed ID: 27100398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors.
    Xu X; Chlebowski RT; Shi J; Barac A; Haque R
    Breast Cancer Res Treat; 2019 Apr; 174(3):785-794. PubMed ID: 30659431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
    Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
    JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endocrine therapy use and cardiovascular risk in postmenopausal breast cancer survivors.
    Matthews AA; Peacock Hinton S; Stanway S; Lyon AR; Smeeth L; Lund JL; Bhaskaran K
    Heart; 2021 Aug; 107(16):1327-1335. PubMed ID: 33177117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer.
    Rillamas-Sun E; Kwan ML; Iribarren C; Cheng R; Neugebauer R; Rana JS; Nguyen-Huynh M; Shi Z; Laurent CA; Lee VS; Roh JM; Huang Y; Shen H; Hershman DL; Kushi LH; Greenlee H
    Breast Cancer Res Treat; 2023 Aug; 201(1):117-126. PubMed ID: 37326764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aromatase inhibitors use and risk for cardiovascular disease in breast cancer patients: A population-based cohort study.
    Sund M; Garcia-Argibay M; Garmo H; Ahlgren J; Wennstig AK; Fredriksson I; Lindman H; Valachis A
    Breast; 2021 Oct; 59():157-164. PubMed ID: 34265496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors.
    Chlebowski RT; Schottinger JE; Shi J; Chung J; Haque R
    Cancer; 2015 Jul; 121(13):2147-55. PubMed ID: 25757699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of dementia among postmenopausal breast cancer survivors treated with aromatase inhibitors versus tamoxifen: a cohort study using primary care data from the UK.
    Bromley SE; Matthews A; Smeeth L; Stanway S; Bhaskaran K
    J Cancer Surviv; 2019 Aug; 13(4):632-640. PubMed ID: 31321612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatase inhibitors alone or sequentially combined with tamoxifen in postmenopausal early breast cancer compared with tamoxifen or placebo - Meta-analyses on efficacy and adverse events based on randomized clinical trials.
    Rydén L; Heibert Arnlind M; Vitols S; Höistad M; Ahlgren J
    Breast; 2016 Apr; 26():106-14. PubMed ID: 27017249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer: A Population-Based Cohort Study.
    Khosrow-Khavar F; Filion KB; Bouganim N; Suissa S; Azoulay L
    Circulation; 2020 Feb; 141(7):549-559. PubMed ID: 32065766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review.
    Matthews A; Stanway S; Farmer RE; Strongman H; Thomas S; Lyon AR; Smeeth L; Bhaskaran K
    BMJ; 2018 Oct; 363():k3845. PubMed ID: 30297439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of aromatase inhibitors and tamoxifen in reducing subsequent breast cancer.
    Haque R; Ahmed SA; Fisher A; Avila CC; Shi J; Guo A; Craig Cheetham T; Schottinger JE
    Cancer Med; 2012 Dec; 1(3):318-27. PubMed ID: 23342281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.
    Ingle JN
    Breast; 2013 Aug; 22 Suppl 2():S180-3. PubMed ID: 24074784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women.
    Gibson LJ; Dawson C; Lawrence DH; Bliss JM
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003370. PubMed ID: 17253488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post-menopausal women with early stage breast cancer.
    Abdel-Qadir H; Amir E; Fischer HD; Fu L; Austin PC; Harvey PJ; Rochon PA; Lee DS; Anderson GM
    Eur J Cancer; 2016 Nov; 68():11-21. PubMed ID: 27693889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimal duration of endocrine therapy with extended aromatase inhibitors for postmenopausal patients with hormone receptor-positive breast cancer: a meta-analysis.
    Chen J; Zhang X; Lu Y; Zhang T; Ouyang Z; Sun Q
    Breast Cancer; 2021 May; 28(3):630-643. PubMed ID: 33387283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hormone therapy and osteoporosis in breast cancer survivors: assessment of risk and adherence to screening recommendations.
    Hamood R; Hamood H; Merhasin I; Keinan-Boker L
    Osteoporos Int; 2019 Jan; 30(1):187-200. PubMed ID: 30413856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
    Nabholtz JM; Gligorov J
    Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors.
    Wang TF; Clarke AE; Awan AA; Tanuseputro P; Carrier M; Sood MM
    JAMA Netw Open; 2022 Jun; 5(6):e2219128. PubMed ID: 35763294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.